.png)
（ 母液浓度为 40 mg/mL ）, 如您需要配置的浓度超过该产品的溶解度，请先与我们客服联系。| 中文名称: | 血管紧张素片断 1-7 乙酸盐 水合物 促销 一键复制产品信息 | ||||
|---|---|---|---|---|---|
| 英文名称: | Angiotensin Fragment 1-7 acetate salt hydrate | ||||
| 别名: | 血管紧张素片断 1-7 乙酸盐 水合物 Angiotensin Fragment 1-7 acetate salt hydrate | ||||
| CAS No: | 51833-78-4 | 分子式: | C41H62N12O11.XC2H4O2.YH2O | 分子量: | 899.00 |
| CAS No: | 51833-78-4 | ||||
| 分子式: | C41H62N12O11.XC2H4O2.YH2O | ||||
| 分子量: | 899.00 | ||||
包装规格：
1mg 5mg 25mg in glass bottle
产品描述：
基本信息
|
产品编号： |
A10084 |
||||
|
产品名称： |
Angiotensin Fragment 1-7 acetate salt hydrate |
||||
|
CAS: |
51833-78-4 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
两年 |
||
|
分子量 |
899.00 |
-20℃ |
一个月 |
||
|
化学名： |
Angiotensin II, 5-L-isoleucine-8-de-L-phenylalanine- |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
Insoluble |
|||
|
Ethanol |
Insoluble |
||||
|
Water |
50mg/mL (55.61mM) |
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
1.1123mL |
5.5617mL |
11.1235mL |
|
5mM |
0.2225mL |
1.1123mL |
2.2247mL |
|
10mM |
0.1112mL |
0.5562mL |
1.1123mL |
|
50mM |
0.0222mL |
0.1112mL |
0.2225mL |
生物活性
|
产品描述 |
一种AT2受体激动剂。 |
|
|
靶点 |
Mas receptor |
ACE 0.65μM |
|
体外研究 |
Angiotensin 1-7 (Ang-(1-7)) inhibits cultured vascular smooth muscle cell growth, whereas equal molar concentration of Ang II stimulates cell growth. Angiotensin 1-7 (Ang 1-7) abrogates the methylglyoxal-modified albumin (MGA)-stimulated myofibroblast phenotype by inhibiting the chronic stimulation of the TGF-β-ERK pathway in NRK-52E cells. Angiotensin 1-7 signals through the Mas receptor ( MasR) in opposition to Ang II/angiotensin II type 1 receptor (AT1R), promoting anti-inflammatory,vasodilatory, and neuroprotective effects |
|
|
体内研究 |
Daily Angiotensin 1-7 (Ang-(1-7)) treatment (0.01-0.06mg/kg) results in significant amelioration of DSS-induced colitis. Colitis-associated phosphorylation of p38, ERK1/2 and Akt is reduced by Ang 1-7 treatment. |
|
推荐实验方法(仅供参考)
|
Kinase Assay |
Competition assays using purified canine ACE are determined using a fixed concentration of the substrate Hip-His-Leu (1mM) and varying the concentrations of the competing agents [Lisinopril (0.1 to 100nM), Angiotensin (1-7) (10nM to 10μM), or Sar1 , Thr8 -Ang II (10nM to 10μM)]. Inhibitory constants (IC50) are determined from the respective competition curves. To study the effect of Angiotensin (1-7) on BK metabolism in intact coronary rings, 125I-[Tyr0 ]-BK (final concentration of 1nM) is added to the tubes containing three rings preincubated with 1mL Krebs' buffer and aerated with 95% O2 and 5% CO2 at 37°C. Lisinopril (2μM), Angiotensin (1-7) (2μM), or Krebs' buffer as control are added to the rings 10 minutes before addition of the radiolabeled BK. Aliquots of the incubation medium are removed at 5, 10, and 20 minutes and diluted with 1% HFBA to inhibit peptidase activity. |
|
|
|
|
Cell Assay |
500μM Methylglyoxal is incubated with 100μM BSA dissolved in phosphate buffered saline (PBS) for 24 hours, then washed on 10 kDa filters to remove excess methyl glyoxal, reconstituted with DMEM/F12 serum free media and passed through a 0.2μMicron filter. TGF-β (5ng/mL) is prepared to treat cells in a subset of experiments. Cells are co-treated with one or combinations of the following: Angiotensin (1-7) (100nM), D-Ala7-Ang-(1-7) (10μM), ERK1/2 kinase inhibitor, PD 98059 (1 μ M), TGF-β receptor kinase inhibitor; SB525334 (1μM), the AT1 receptor antagonist Losartan (1μM), the renin inhibitor Aliskerin (1μM) and the ACE inhibitor Lisinopril (1μM). |
|
|
|
|
Animal Administration |
Mice Male and female BALB/c mice (1:1 ratio, 6-10 weeks old, mean weight 20 g.) are used. Angiotensin fragment 1-7 acetate salt hydrate (Ang 1-7) is dissolved in 0.9% saline (vehicle) at 1mg/mL and stored at -80°C. Various doses (0.01, 0.06, 0.1, 0.3 and 1mg/kg) are freshly prepared from the stock each day of the experiment, and administered to mice by daily intra-peritoneal (i.p) injections in a volume of 500μL per injection, either before (prophylactic approach) or after (treatment approach) DSS treatment. A779 (MAS-1 R antagonist) is similarly dissolved in distilled water at 1mg/mL and stored at -80°C. A freshly prepared dose of 1mg/kg is administered to a second group of mice by daily i.p injections in a volume of 500μL daily (for 4 days) along with colitis induction (prophylactic approach). A third group of mice receive DSS containing water and daily i.p injections of 0.9% saline (vehicle). The fourth group receive DSS containing water along with daily i.p injections with Dexamethasone (DEX) at doses of 0.01-1.0mg/kg or its vehicle (0.9% saline) (prophylactic approach). Rats Twenty six ovariectomized female Wistar rats weighing 200±20 g are used. Angiotensin (1-7) is administered intravenously by a microsyringe pump at two different continuous doses of 100 and 300ng/kg/min after antagonist/saline infusion. Each dose is infused for 15 min; and MAP, RPP, and RBF are recorded during Angiotensin (1-7) infusion and the last 3-5 min of each dose measured as “response to Angiotensin (1-7) infusion”. During Angiotensin (1-7) infusion, RPP is sustained at preAng1-7 infusion levels via an adjustable aortic clamp. |
保存条件：
-20℃
UN码：
HazardClass：
危害声明：
安全说明：
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
(2).jpg)
体内配方的制备方法: 取 50μLDMSO 母液，添加 300 μLPEG300 混匀澄清，再加 50μLTween80, 混匀澄清，再加 600μLSaline/PBS/ddH2O 混匀澄清
方案所需的各种助溶剂如： DMSO ， PEG300 / PEG400 ， Tween 80 ， SBE-β-CD ， 玉米油 等， 均可点击跳转或在网站搜索购买。
母液，添加 300 μLPEG300 混匀澄清，再加 50μLTween80, 混匀澄清，再加 600μLSaline/PBS/ddH2O 混匀澄清方案所需的各种助溶剂如： DMSO ， PEG300 / PEG400 ， Tween 80 ， SBE-β-CD ， 玉米油 等， 均可点击跳转或在网站搜索购买。
以上为“动物实验计算换算器”的使用方法举例，并不是具体某个试剂的配制，请根据您的实验动物和给药方式选择适当的溶解方案。
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL Saline/PBS/ddH2O，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
剂量转换
对于不同动物的给药剂量换算，您也可以参考 更多
